Morgan Stanley Maintains Overweight on NextCure, Raises Price Target to $52

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and raises the price target from $33 to $52.

Benzinga · 11/13/2019 13:13

Morgan Stanley maintains NextCure (NASDAQ:NXTC) with a Overweight and raises the price target from $33 to $52.